Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Melanoma 39Neoplasms 16Neoplasm Metastasis 8Colorectal Neoplasms 5Thyroid Neoplasms 3Skin Neoplasms 2Recurrence 2Leukemia, Hairy Cell 2Wilms Tumor 1Urinary Bladder Neoplasms 1Thyroid cancer, follicular 1Thyroid Cancer, Papillary 1Skin Diseases 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Pancreatic Neoplasms 1Osteosarcoma 1Noonan syndrome 3 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Neoplasms, Unknown Primary 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Histiocytosis, Langerhans-Cell 1Heterotaxy Syndrome 1Hepatoblastoma 1Glioma 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Recurrence × Vemurafenib × Clear all
NCT01748149 2025-08-03

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

University of California, San Francisco

Phase EARLY_PHASE1 Completed
40 enrolled

Recurrence

NCT01531361 2021-01-22

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

M.D. Anderson Cancer Center

Phase 1 Completed
46 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡